NAV

Bacillus calmette-guerin substrain danish 1331 live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bacillus calmette-guerin substrain danish 1331 live antigen
Accession Number
DB12386
Description

BCG SSI has been used in trials studying Tuberculosis.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • BCG (SSI strain)
  • BCG SSI

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Amantadine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
4CGF0IDN3W
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911329

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingPreventionBCG Vaccination Reaction / Tuberculosis (TB)1
3RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Heterologous Immunity / Immunosenescence / Morbidity / Non-specific Effects of Vaccines / Vaccine Preventable Disease1
2CompletedPreventionTuberculosis (TB)1
1CompletedPreventionTuberculosis (TB)1
Not AvailableCompletedNot AvailableTuberculosis (TB)2
Not AvailableCompletedPreventionTuberculosis (TB)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 16:10 / Updated on June 12, 2020 10:53

94